

AstraZeneca partners with Alveofit for lung diseases management

16 August 2022 | News

To scale up the diagnosis and treatment of lung diseases in India



Under the aegis of its A Catalyst network, AstraZeneca India has announced its partnership with Alveofit, a SaaS-IoT enabled respiratory healthcare platform, to offer IoT-enabled handheld spirometers at hospitals across the country.

The partnership aims to embed the latest technological advancements in diagnosing and managing lung disorders and associated non-communicable diseases like asthma, pulmonary fibrosis and COPD.

As a part of this partnership with Alveofit, AstraZeneca will provide Alveofit IoT-enabled handheld spirometers to the clinics and last mile hospitals to enable point-of-care spirometry for the optimised management of different lung-associated noncommunicable diseases. This will help track patients remotely and even conduct telespirometry with comprehensive care management solutions.

Partnering with Alveofit, AstraZeneca has deployed spirometers at selected hospitals across the country. This includes ESIC hospitals for industrial employees, Command and Military Hospitals, General Hospitals and last mile clinics in cities like Lucknow, Chennai, Nagpur, Delhi, Ahmedabad and Kolkata. In a pilot project conducted before starting this initiative, 2800+ patients were tested and around 35-40 per cent were diagnosed with lung issues across all the age groups right from 10-12 years old to 85-90 years old through this deployment.